A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen)

Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial

(2010) V. Hess et al.   ANNALS OF ONCOLOGY

Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2010) S. Cascinu et al.   ANNALS OF ONCOLOGY

An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change?

(2010) Michele Reni et al.   ANTI-CANCER DRUGS

Treatment trends in metastatic pancreatic cancer patients: Is it time to change?

(2010) Michele Reni et al.   DIGESTIVE AND LIVER DISEASE

Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study

(2010) Giuseppe Colucci et al.   JOURNAL OF CLINICAL ONCOLOGY

Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma

(2009) Michele Reni et al.   CANCER

Randomized Phase II Study of Gemcitabine Administered at a Fixed Dose Rate or in Combination With Cisplatin, Docetaxel, or Irinotecan in Patients With Metastatic Pancreatic Cancer: CALGB 89904

(2009) Matthew H. Kulke et al.   JOURNAL OF CLINICAL ONCOLOGY

Incremental Advance or Seismic Shift? The Need to Raise the Bar of Efficacy for Drug Approval

(2009) Alberto Sobrero et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group

(2009) Elizabeth Poplin et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer

(2009) David Cunningham et al.   JOURNAL OF CLINICAL ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer

(2008) David Cunningham et al.   NEW ENGLAND JOURNAL OF MEDICINE

Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer

(2007) S. Boeck et al.   ANNALS OF ONCOLOGY